IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutics Jg. 15; H. 10; S. 2450
Hauptverfasser: Malvaso, Dalma, Calabrese, Laura, Chiricozzi, Andrea, Antonelli, Flaminia, Coscarella, Giulia, Rubegni, Pietro, Peris, Ketty
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Basel MDPI AG 01.10.2023
MDPI
Schlagworte:
bimekizumab
biologics
brodalumab
Chemokines
Cytokines
Disease
Health aspects
hidradenitis suppurativa
IL-17 inhibitors
Inflammation
Localization
Metabolic syndrome
Monoclonal antibodies
Neutrophils
Pathogenesis
Pathophysiology
Psoriasis
Review
secukinumab
Skin
Skin diseases
Tumor necrosis factor
Tumor necrosis factor-TNF
ISSN:1999-4923, 1999-4923
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients. Numerous clinical trials are currently ongoing to test novel therapeutic targets in HS. The IL-17-mediated cascade is the target of several biologic agents that have shown efficacy and safety in treating moderate-to-severe HS. Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15102450